靶向B细胞治疗系统性红斑狼疮的研究进展  

Advances in B-cell targeting therapy for systemic lupus erythematosus

作　　者：李赫[1] 尹晶[1] 李崇巍[1] LI He;YIN Jing;LI Chongwei(Department of Rheumatology and Immunology,Tianjin Children's Hospital,Tianjin 300134,China)

机构地区：[1]天津市儿童医院风湿免疫科,天津300134

出　　处：《沈阳医学院学报》2021年第5期482-485,共4页Journal of Shenyang Medical College

摘　　要：系统性红斑狼疮(SLE)是一种慢性全身性自身免疫性疾病。B细胞过度活化导致免疫失衡是SLE发病的直接原因。因此,B细胞成为开发SLE新疗法的主要靶点。目前研发并应用于SLE治疗的生物制剂主要包括针对B细胞表面抗原、B细胞相关细胞因子和其辅助分子等,而细胞内小分子靶向药物也极具临床潜力。这篇综述将介绍靶向B细胞治疗SLE的研究进展。Systemic lupus erythematosus(SLE)is a chronic systemic autoimmune disease.Overactivation of B cells leads to immune imbalance,which is the main pathogenesis of SLE.Therefore,B cells are major targets for the development of new therapies for SLE.Currently,biological agents developed and applied in SLE therapy mainly include B-cell surface antigens,B-cell related cytokines and their auxiliary molecules.And intracellular small-molecule targeted drugs also have great clinical potential.This article reviews the advances in B-cell targeting therapy for SLE.

关 键 词：系统性红斑狼疮 靶向B细胞 生物制剂 

分 类 号：R392[医药卫生—免疫学]